Meningeal Neoplasms: Clinical Trials

412 trials for Meningeal Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

141 completed, 106 recruiting, 43 unknown, 38 terminated. 146 Phase 2, 118 Phase 1, 78 Not applicable, 14 Phase 3, 10 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2146Completed 53, Recruiting 37, Terminated 16, Active not recruiting 14, Not yet recruiting 12, Unknown 10, Withdrawn 4
Phase 1118Completed 53, Recruiting 22, Active not recruiting 15, Terminated 15, Not yet recruiting 5, Unknown 4, Withdrawn 3, Suspended 1
Not applicable78Recruiting 33, Completed 13, Unknown 11, Not yet recruiting 9, Withdrawn 5, Active not recruiting 3, Terminated 3, Enrolling by invitation 1
Phase 314Completed 7, Unknown 3, Terminated 2, Active not recruiting 1, Recruiting 1
Phase 410Recruiting 4, Unknown 4, Active not recruiting 1, Completed 1
Early Phase 19Completed 2, Not yet recruiting 2, Recruiting 2, Terminated 2, Active not recruiting 1

Follow Meningeal Neoplasms: new trials by email Literature Review of Meningeal Neoplasms trials Research Report on Meningeal Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma
JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease
Phase 1 / Phase 2Not yet recruitingJubilant Therapeutics Inc.1132028-04-012026-08-07
ctDNA-Guided Intraventricular Therapy for CNS Malignancies
CSF ctDNA-Guided Clinical Management - Leptomeningeal Disease, Glioblastoma
Not applicableNot yet recruitingAlireza Mansouri772027-01-012026-07-08
Ceritinib Treatment for Recurrent Meningiomas
Ceritinib - Recurrent Meningioma, Grade I and Grade II
Phase 2Not yet recruitingKevin Petrecca102027-01-012026-10-23
A Study of ONC201 for Refractory Meningioma
ONC201 - Meningioma, Refractory Meningioma
Phase 2WithdrawnUniversity of Nebraska2026-12-012026-01-26
Wearable-Triggered Digital Safety Net for Real-Time Monitoring & Intervention in Leptomeningeal Metastasis
Calibration Phase, Stepped Wedge Intervention Phase - Leptomeningeal Metastasis
Not applicableNot yet recruitingCase Comprehensive Cancer Center482026-11-012026-09-03
China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm
Tumor resection followed by aneurysm treatment, Aneurysm treatment followed by tumor resection, Observation - Unruptured Intracranial Aneurysms, Pituitary Neuroendocrine Tumor
Active not recruitingCheng sen6082026-10-202026-10-21
BRain-AVOidant Proton Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumor Malignancies
Radiation Treatments Using Brain- Avoidant Proton Craniospinal Irradiation (BRAVO- pCSI) - Leptomeningeal Metastasis, Breast Cancer
Not applicableRecruitingUniversity of Miami402026-10-132026-10-23
Preoperative Embolization for Highly Vascular Brain Tumors
Preoperative Endovascular Embolization - Brain Neoplasms, Meningioma
Not applicableNot yet recruitingAssiut University552026-10-012026-09-17
Pharmacoscopy for Patients With Refractory Primary Brain Tumors
Pharmacoscopy 1.0 - Brain (Nervous System) Cancers, Glioblastoma
Phase 2RecruitingUniversity of Zurich402026-09-112026-09-21
A Study of SX-682 in Combination With Proton Craniospinal Irradiation (pCSI) in People With Leptomeningeal Disease
SX-682, Proton Craniospinal Irradiation (pCSI) - Leptomeningeal Disease (LMD)
Phase 1RecruitingMemorial Sloan Kettering Cancer Center402026-09-042026-09-11
Combined Intrathecal and Systemic Therapy With Trastuzumab Rezetecan for Leptomeningeal Metastases
Intrathecal and systemic administration of Trastuzumab Rezetecan - Leptomeningeal Metastases, Solid Tumors
Phase 2Not yet recruitingJiuda Zhao282026-09-012026-09-22
Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI.
Thiotepa - Leptomeningeal Metastasis
Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital502026-09-012026-08-21
B7-H3.CD28Z.CART in CNS Neoplasms
B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide - Central Nervous System Neoplasms, Brain Tumor
Phase 1RecruitingRobbie Majzner702026-09-012026-09-03
IN10018 in Combination With Dalpiciclib for Progressive Meningiomas
Ifebemtinib, Dalpiciclib - Meningioma, CDK4/6 Inhibitor
Phase 1RecruitingCapital Medical University242026-08-312026-10-21
Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC
Ga-68- DOTATATE, Ga-68-DOTATOC - Meningioma
Phase 2WithdrawnWeill Medical College of Cornell University2026-08-012026-08-31
Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD
cDC1 Vaccine, Trastuzumab, Nivolumab - Breast Cancer, Leptomeningeal Disease
Phase 2RecruitingH. Lee Moffitt Cancer Center and Research Institute302026-08-012026-07-10
Luvometinib in Combination With Serplulimab for NF2-Related Tumors
Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2
Phase 1 / Phase 2Not yet recruitingBeijing Tiantan Hospital302026-07-312026-07-16
DEXmedetomidine for Postoperative Analgesia and Delirium Prevention After NEUROsurgery (DEX-NEURO Trial)
Dexmedetomidine, Normal Saline (0.9% NaCl) - Neurosurgery, Brain Cancer
Not applicableNot yet recruitingUniversity of Malaya602026-07-222026-02-09
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)
Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma
Phase 2Not yet recruitingBeijing Tiantan Hospital2002026-07-182026-07-20
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
JZP3507 - Meningioma
Phase 2RecruitingJazz Pharmaceuticals302026-07-162026-07-30

Showing 20 of 412. Sign in to see all of them.

Narrower conditions

Meningioma (240)  ·  Meningeal Carcinomatosis (146)  ·  Brain Neoplasms (140)  ·  Glioma (71)  ·  Glioblastoma (61)  ·  Astrocytoma (60)  ·  Central Nervous System Neoplasms (59)  ·  Oligodendroglioma (55)  ·  Medulloblastoma (54)  ·  Ependymoma (52)  ·  Carcinoma, Non-Small-Cell Lung (40)  ·  Breast Neoplasms (39)  ·  Choroid Plexus Neoplasms (34)  ·  Gliosarcoma (34)

Broader conditions

Neoplasms by Site (411)  ·  Nervous System Diseases (411)  ·  Nervous System Neoplasms (410)  ·  Neoplasms (384)  ·  Central Nervous System Neoplasms (353)  ·  Neoplasms by Histologic Type (273)  ·  Neoplasms, Nerve Tissue (261)  ·  Neoplasms, Vascular Tissue (240)  ·  Central Nervous System Diseases (164)  ·  Brain Diseases (160)  ·  Neuroectodermal Tumors (140)  ·  Neoplasms, Germ Cell and Embryonal (134)  ·  Neoplasms, Glandular and Epithelial (122)  ·  Neoplasms, Neuroepithelial (116)

Interventions

Magnetic Resonance Spectroscopy (23)  ·  Pemetrexed (20)  ·  Bevacizumab (17)  ·  Radiotherapy (13)  ·  Specimen Handling (11)  ·  Spinal Puncture (9)  ·  Cyclophosphamide (8)  ·  Everolimus (7)  ·  Methotrexate (7)  ·  Nivolumab (7)  ·  Radiosurgery (7)  ·  Radiotherapy, Intensity-Modulated (7)  ·  Temozolomide (7)  ·  Topotecan (7)  ·  Trastuzumab (7)

Sponsors

National Cancer Institute (NCI) (19)  ·  M.D. Anderson Cancer Center (11)  ·  Memorial Sloan Kettering Cancer Center (10)  ·  Guangzhou Medical University (8)  ·  Wake Forest University Health Sciences (8)  ·  Beijing Tiantan Hospital (7)  ·  City of Hope Medical Center (7)  ·  Duke University (7)  ·  Massachusetts General Hospital (7)  ·  NYU Langone Health (7)  ·  Central Hospital, Nancy, France (6)  ·  Northwestern University (6)  ·  H. Lee Moffitt Cancer Center and Research Institute (5)  ·  The First Hospital of Jilin University (5)  ·  Case Comprehensive Cancer Center (4)

Countries

United States (207)  ·  China (70)  ·  France (30)  ·  Canada (13)  ·  Germany (11)  ·  Switzerland (10)  ·  Italy (8)  ·  Netherlands (7)  ·  United Kingdom (6)  ·  Spain (5)  ·  Taiwan (5)  ·  Austria (4)  ·  South Korea (4)  ·  Australia (3)  ·  Denmark (3)

Top investigators

Darell D. Bigner, MD, PhD (4)  ·  Edward G. Shaw, MD (3)  ·  Priscilla Brastianos, MD (3)  ·  Priya Kumthekar, MD (3)  ·  Thomas Kaley, MD (3)  ·  Zhenyu Pan (3)  ·  Zhenyu Pan, Professor (3)  ·  Alexander Dmitriev, MD (2)  ·  Anhua Wu, MD (2)  ·  Barbara J O'Brien, MD (2)  ·  D. Brandsma, MD, PhD (2)  ·  Danielle Eekers (2)  ·  Harry T Whelan, MD (2)  ·  Helen A Shih, MD (2)  ·  Henry S. Friedman, MD (2)

Results publications

PMID 27243238, PMID 31809241, PMID 15117425, PMID 26334749, PMID 26827696, PMID 29151359, PMID 30059262, PMID 9533527, PMID 10501910, PMID 11273919, PMID 11410496, PMID 11810123, PMID 11937001, PMID 14059058, PMID 1447744, PMID 14750917, PMID 15118073, PMID 15118125, PMID 15844174, PMID 15886314, PMID 15897941, PMID 16127110, PMID 16391300, PMID 16533779, PMID 16549835, PMID 16642476, PMID 16855840, PMID 16914578, PMID 16983123, PMID 17308042, PMID 17312328, PMID 17315026, PMID 17374728, PMID 17894407, PMID 17909804, PMID 18056189, PMID 18172267, PMID 18447671, PMID 18470481, PMID 18633018, PMID 18728566, PMID 19470276, PMID 19738466, PMID 20087963, PMID 20573926, PMID 20627894, PMID 20689429, PMID 21062428, PMID 21599552, PMID 21632855

NIH funding

P30CA033572 (4), P30CA043703 (3), U01CA062399 (3), U10CA032102 (3), U10CA081851 (3), 2009 (2), 2019 (2), P30CA060553 (2), P30CA138292 (2), R01CA167632 (2), U01CA081457 (2), U10CA180868 (2), 2005 (1), 2008 (1), 2014 (1)